Across the training, validation, and prospective cohorts, the EVM signature showed similar performance for classifying treatment response when applied to different BC subtypes (AUC = 0.9444, 95% CI = 0.8681–1.0000 for hormone receptor-positive (HR + ); AUC = 0.8674, 95% CI = 0.7307–1.0000 for human epidermal growth factor receptor 2-positive (HER2 + ); AUC = 0.9026, 95% CI = 0.7662–1.0000 for triple-negative breast cancer (TNBC); Fig. 5d, e). The gene discussed is NR4A1; the disease is triple-negative breast carcinoma.